{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T16:05:28Z","timestamp":1788969928006,"version":"build-2803163510"},"reference-count":97,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.autrev.2026.104056","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T15:27:42Z","timestamp":1775575662000},"page":"104056","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Anti-CD52 therapy of rheumatic diseases: Revisited in the era of immune reset"],"prefix":"10.1016","volume":"25","author":[{"given":"Fadi","family":"Hassan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Isaacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad E.","family":"Naffaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.autrev.2026.104056_bb0005","doi-asserted-by":"crossref","first-page":"6088","DOI":"10.1074\/jbc.270.11.6088","article-title":"Primary structure of CD52","volume":"270","author":"Treumann","year":"1995","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.autrev.2026.104056_bb0010","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1042\/bj2930633","article-title":"Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis","volume":"293","author":"Xia","year":"1993","journal-title":"Biochem J"},{"issue":"3","key":"10.1016\/j.autrev.2026.104056_bb0015","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/146532401753174098","article-title":"The CD52 antigen and development of the CAMPATH antibodies","volume":"3","author":"Hale","year":"2001","journal-title":"CytoTherapy"},{"issue":"5","key":"10.1016\/j.autrev.2026.104056_bb0020","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1182\/blood.V100.5.1715.h81702001715_1715_1720","article-title":"Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab","volume":"100","author":"Buggins","year":"2002","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.autrev.2026.104056_bb0025","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1182\/blood-2002-04-1093","article-title":"Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation","volume":"101","author":"Ratzinger","year":"2003","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.autrev.2026.104056_bb0030","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1182\/blood.V82.3.807.807","article-title":"Effect of Campath-1H antibody on human hematopoietic progenitors in vitro","volume":"82","author":"Gilleece","year":"1993","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.autrev.2026.104056_bb0035","doi-asserted-by":"crossref","first-page":"4684","DOI":"10.1182\/blood.V88.12.4684.bloodjournal88124684","article-title":"Surface and mRNA expression of the CD52 antigen by human eosinophils but not by neutrophils","volume":"88","author":"Elsner","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2026.104056_bb0040","doi-asserted-by":"crossref","first-page":"7174","DOI":"10.1158\/1078-0432.CCR-06-1275","article-title":"Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H)","volume":"12","author":"Rodig","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.autrev.2026.104056_bb0045","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.surg.2004.06.015","article-title":"Campath-1H in renal transplantation: the university of Wisconsin experience","volume":"136","author":"Knechtle","year":"2004","journal-title":"Surgery"},{"issue":"14","key":"10.1016\/j.autrev.2026.104056_bb0050","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1182\/blood-2009-02-203075","article-title":"Neutrophils express CD52 and exhibit complement-mediated lysis in the presence of alemtuzumab","volume":"114","author":"Ambrose","year":"2009","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.autrev.2026.104056_bb0055","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1365-2567.2009.03115.x","article-title":"Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model","volume":"128","author":"Hu","year":"2009","journal-title":"Immunology"},{"issue":"3","key":"10.1016\/j.autrev.2026.104056_bb0060","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1006\/immu.1994.1054","article-title":"Expression of cell surface markers during differentiation of CD34+, CD38\u2212\/ lo fetal and adult bone marrow cells","volume":"5","author":"Olweus","year":"1994","journal-title":"Immunomethods"},{"issue":"1","key":"10.1016\/j.autrev.2026.104056_bb0065","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/146532400539008","article-title":"Impact on t-cell depletion and CD34+ cell recovery using humanised CD52 monoclonal antibody (CAMPATH-1H) in BM and PSBC collections; comparison with CAMPATH-1M and CAMPATH-1G","volume":"2","author":"Williams","year":"2000","journal-title":"Cytotherapy"},{"issue":"7","key":"10.1016\/j.autrev.2026.104056_bb0070","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1002\/eji.1830210714","article-title":"Characterization of the CAMPATH-1 (CDw52) antigen: biochemical analysis and cDNA cloning reveal an unusually small peptide backbone","volume":"21","author":"Xia","year":"1991","journal-title":"Eur J Immunol"},{"issue":"7","key":"10.1016\/j.autrev.2026.104056_bb0075","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/ni.2610","article-title":"T cell regulation mediated by interaction of soluble CD52 with the inhibitory receptor siglec-10","volume":"14","author":"Bandala-Sanchez","year":"2013","journal-title":"Nat Immunol"},{"issue":"5","key":"10.1016\/j.autrev.2026.104056_bb0080","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1182\/blood-2002-05-1426","article-title":"All-trans-retinoic acid induces CD52 expression in acute promyelocytic leukemia","volume":"101","author":"Li","year":"2003","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.autrev.2026.104056_bb0085","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s00011-017-1032-8","article-title":"The immunological function of CD52 and its targeting in organ transplantation","volume":"66","author":"Zhao","year":"2017","journal-title":"Inflamm Res"},{"issue":"1","key":"10.1016\/j.autrev.2026.104056_bb0090","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/intimm\/7.1.69","article-title":"Cross-linking of the CAMPATH-1 antigen (CD52) triggers activation of normal human t lymphocytes","volume":"7","author":"Rowan","year":"1995","journal-title":"Int Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2026.104056_bb0095","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.clim.2006.05.006","article-title":"CD52 is a novel costimulatory molecule for induction of CD4+ regulatory t cells","volume":"120","author":"Watanabe","year":"2006","journal-title":"Clin Immunol"},{"issue":"7","key":"10.1016\/j.autrev.2026.104056_bb0100","doi-asserted-by":"crossref","first-page":"3710","DOI":"10.4049\/jimmunol.169.7.3710","article-title":"A novel costimulation pathway via the 4C8 antigen for the induction of CD4+ regulatory t cells","volume":"169","author":"Masuyama","year":"2002","journal-title":"J Immunol"},{"issue":"6","key":"10.1016\/j.autrev.2026.104056_bb0105","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1084\/jem.189.6.979","article-title":"Characterization of the 4C8 antigen involved in transendothelial migration of CD26(hi) t cells after tight adhesion to human umbilical vein endothelial cell monolayers","volume":"189","author":"Masuyama","year":"1999","journal-title":"J Exp Med"},{"issue":"3","key":"10.1016\/j.autrev.2026.104056_bb0110","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1046\/j.1365-2567.1998.00615.x","article-title":"Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human b- and t-lymphoma cell lines, and subsequent emergence of CD52-deficient cells","volume":"95","author":"Rowan","year":"1998","journal-title":"Immunology"},{"issue":"2\u20133","key":"10.1016\/j.autrev.2026.104056_bb0115","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ejphar.2005.03.024","article-title":"Alemtuzumab induces enhanced apoptosis in vitro in b-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicity","volume":"514","author":"N\u00fcckel","year":"2005","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"10.1016\/j.autrev.2026.104056_bb0120","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/sj.leu.2404014","article-title":"Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism","volume":"20","author":"Mone","year":"2006","journal-title":"Leukemia"},{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2026.104056_bb0125","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1186\/2047-1440-2-S1-S5","article-title":"Alemtuzumab induction therapy in solid organ transplantation","volume":"2","author":"Friend","year":"2013","journal-title":"Transp Res"},{"issue":"6","key":"10.1016\/j.autrev.2026.104056_bb0130","doi-asserted-by":"crossref","first-page":"783","DOI":"10.2217\/imt.10.68","article-title":"Alemtuzumab in solid organ transplantation and in composite tissue allotransplantation","volume":"2","author":"Weissenbacher","year":"2010","journal-title":"Immunotherapy"},{"issue":"8","key":"10.1016\/j.autrev.2026.104056_bb0135","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1517\/14712598.2011.592824","article-title":"Alemtuzumab in allogeneic hematopoetic stem cell transplantation","volume":"11","author":"Poir\u00e9","year":"2011","journal-title":"Expert Opin Biol Ther"},{"issue":"7","key":"10.1016\/j.autrev.2026.104056_bb0140","doi-asserted-by":"crossref","first-page":"16414","DOI":"10.3390\/ijms160716414","article-title":"Alemtuzumab in multiple sclerosis: mechanism of action and beyond","volume":"16","author":"Ruck","year":"2015","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.autrev.2026.104056_bb0145","doi-asserted-by":"crossref","first-page":"475.e1","DOI":"10.1016\/j.jtct.2021.02.023","article-title":"CD52\/GPI- T-cells are enriched for alloreactive specificity and predict acute graft-versus-host-disease after stem cell transplantation","volume":"27","author":"Kinsella","year":"2021","journal-title":"Transplantation and cellular therapy"},{"issue":"1","key":"10.1016\/j.autrev.2026.104056_bb0150","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/imm.12178","article-title":"Impact of alemtuzumab treatment on the survival and function of human regulatory t cells in vitro","volume":"141","author":"Havari","year":"2014","journal-title":"Immunology"},{"issue":"6","key":"10.1016\/j.autrev.2026.104056_bb0155","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.3390\/cells9061396","article-title":"The meaning of immune reconstitution after alemtuzumab therapy in multiple sclerosis","volume":"9","author":"Rolla","year":"2020","journal-title":"Cells"},{"issue":"12","key":"10.1016\/j.autrev.2026.104056_bb0160","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/0161-5890(93)90155-5","article-title":"Efficient complement-mediated lysis of cells containing the CAMPATH-1 (CDw52) antigen","volume":"30","author":"Xia","year":"1993","journal-title":"Mol Immunol"},{"issue":"4","key":"10.1016\/j.autrev.2026.104056_bb0165","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1042\/bst0231057","article-title":"Clinical trials with CAMPATH-1 and other monoclonal antibodies","volume":"23","author":"Hale","year":"1995","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.autrev.2026.104056_bb0170","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1365-2249.1997.tb08312.x","article-title":"Humanized anti-CD4 monoclonal antibody therapy of autoimmune and inflammatory disease","volume":"110","author":"Isaacs","year":"1997","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2026.104056_bb0175","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1046\/j.1365-2249.1996.d01-876.x","article-title":"A therapeutic human IgG4 monoclonal antibody that depletes target cells in humans","volume":"106","author":"Isaacs","year":"1996","journal-title":"Clin Exp Immunol"},{"issue":"10","key":"10.1016\/j.autrev.2026.104056_bb0180","doi-asserted-by":"crossref","first-page":"6346","DOI":"10.4049\/jimmunol.0901773","article-title":"Regulatory t cell (treg) subsets return in patients with refractory lupus following stem cell transplantation, and TGF-beta-producing CD8+ treg cells are associated with immunological remission of lupus","volume":"183","author":"Zhang","year":"2009","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.autrev.2026.104056_bb0185","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/j.0303-6987.2004.0165.x","article-title":"Atypical lymphocytic lobular panniculitis","volume":"31","author":"Magro","year":"2004","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.autrev.2026.104056_bb0190","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X20969261","article-title":"Shared development of targeted therapies among autoimmune and inflammatory diseases: a systematic repurposing analysis","volume":"12","author":"Petitdemange","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"1","key":"10.1016\/j.autrev.2026.104056_bb0195","article-title":"T cells in rheumatoid arthritis","volume":"10","author":"Cope","year":"2008","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1016\/j.autrev.2026.104056_bb0200","doi-asserted-by":"crossref","first-page":"905","DOI":"10.3390\/ijms23020905","article-title":"Rheumatoid arthritis: pathogenic roles of diverse immune cells","volume":"23","author":"Jang","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"8822","key":"10.1016\/j.autrev.2026.104056_bb0205","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/0140-6736(92)92294-P","article-title":"Humanised monoclonal antibody therapy for rheumatoid arthritis","volume":"340","author":"Isaacs","year":"1992","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.autrev.2026.104056_bb0210","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1002\/art.1780381110","article-title":"CAMPATH-1H, a humanized monoclonal antibody, in refractory rheumatoid arthritis: an intravenous dose-escalation study","volume":"38","author":"Weinblatt","year":"1995","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.autrev.2026.104056_bb0215","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1002\/art.1780380903","article-title":"Treatment of active refractory rheumatoid arthritis with humanized monoclonal antibody CAMPATH-1H administered by daily subcutaneous injection","volume":"38","author":"Matteson","year":"1995","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.autrev.2026.104056_bb0220","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1093\/rheumatology\/35.3.231","article-title":"Therapy with monoclonal antibodies to t cells in rheumatoid arthritis: an intravenous dose-ranging study of a partially humanised anti-CD52 monoclonal antibody (CAMPATH-1H)","volume":"35","author":"Isaacs","year":"1996","journal-title":"Br J Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104056_bb0225","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1046\/j.1365-2567.1996.d01-650.x","article-title":"Repopulation of blood lymphocyte subpopulations in rheumatoid arthritis patients treated with CAMPATH-1H","volume":"88","author":"Brett","year":"1996","journal-title":"Immunology"},{"issue":"3","key":"10.1016\/j.autrev.2026.104056_bb0230","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/intimm\/8.3.325","article-title":"Emergence of CD52-, glycosylphosphatidylinositol-anchor-deficient lymphocytes in rheumatoid arthritis patients following Campath-1H treatment","volume":"8","author":"Brett","year":"1996","journal-title":"Int Immunol"},{"issue":"9","key":"10.1016\/j.autrev.2026.104056_bb0235","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1002\/1529-0131(200109)44:9<1998::AID-ART348>3.0.CO;2-T","article-title":"Morbidity and mortality in rheumatoid arthritis patients with prolonged and profound therapy-induced lymphopenia","volume":"44","author":"Isaacs","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.autrev.2026.104056_bb0240","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/art.23122","article-title":"Morbidity and mortality in rheumatoid arthritis patients with prolonged therapy-induced lymphopenia: twelve-year outcomes","volume":"58","author":"Lorenzi","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.autrev.2026.104056_bb0245","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1093\/rheumatology\/kes038","article-title":"Immunity 12 years after alemtuzumab in RA: CD5+ b-cell depletion, thymus-dependent t-cell reconstitution and normal vaccine responses","volume":"51","author":"Anderson","year":"2012","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.autrev.2026.104056_bb0250","doi-asserted-by":"crossref","first-page":"R80","DOI":"10.1186\/ar1452","article-title":"Interleukin-7 deficiency in rheumatoid arthritis: consequences for therapy-induced lymphopenia","volume":"7","author":"Ponchel","year":"2005","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"10.1016\/j.autrev.2026.104056_bb0255","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1177\/0961203306075615","article-title":"Exploring new territory: considering the future of systemic lupus erythematosus therapy","volume":"16","author":"Schneider","year":"2007","journal-title":"Lupus"},{"issue":"3","key":"10.1016\/j.autrev.2026.104056_bb0260","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/BOR.0b013e328337c3d6","article-title":"Innovative therapies for systemic sclerosis","volume":"22","author":"Ong","year":"2010","journal-title":"Curr Opin Rheumatol"},{"issue":"5","key":"10.1016\/j.autrev.2026.104056_bb0265","first-page":"521","article-title":"Use of alemtuzumab to treat systemic lupus erythematosus complicated by hemophagocytic lymphohistiocytosis","volume":"21","author":"Keith","year":"2012","journal-title":"Lupus"},{"issue":"6","key":"10.1016\/j.autrev.2026.104056_bb0270","first-page":"1103","article-title":"Monoclonal antibody therapy of diffuse cutaneous scleroderma with CAMPATH-1H","volume":"23","author":"Isaacs","year":"1996","journal-title":"J Rheumatol"},{"issue":"12","key":"10.1016\/j.autrev.2026.104056_bb0275","first-page":"2258","article-title":"Regulation of monocyte adhesion and type i interferon signaling by CD52 in patients with systemic sclerosis","volume":"73","author":"Rudnik","year":"2021","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.autrev.2026.104056_bb0280","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1056\/NEJM199007263230407","article-title":"Monoclonal-antibody therapy in systemic vasculitis","volume":"323","author":"Mathieson","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2026.104056_bb0285","doi-asserted-by":"crossref","unstructured":"Lockwood CM, Thiru S, Stewart S, Hale G, Isaacs J, Wraight P, Elliott J, Waldmann H. Treatment of refractory wegener's granulomatosis with humanized monoclonal antibodies. QJM 1996;89(12):903\u201312.","DOI":"10.1093\/qjmed\/89.12.903"},{"issue":"12","key":"10.1016\/j.autrev.2026.104056_bb0290","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1038\/sj.eye.6702330","article-title":"The use of campath in severe peripheral ulcerative keratitis associated with wegener\u2019s granulomatosis","volume":"20","author":"Wertheim","year":"2006","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.autrev.2026.104056_bb0295","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1136\/ard.2007.081661","article-title":"Long-term follow-up of relapsing\/refractory ANCA-associated vasculitis treated with alemtuzumab","volume":"67","author":"Walsh","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"Suppl. 3","key":"10.1016\/j.autrev.2026.104056_bb0300","doi-asserted-by":"crossref","first-page":"iii28","DOI":"10.1093\/rheumatology\/keab180","article-title":"A critical beat in eosinophilic granulomatosis with polyangiitis","volume":"60","author":"Egan","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2026.104056_bb0305","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-022-02761-6","article-title":"Alemtuzumab for refractory primary systemic vasculitis\u2014a randomised controlled dose ranging clinical trial of efficacy and safety (ALEVIATE)","volume":"24","author":"Gopaluni","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2026.104056_bb0310","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/brain\/awp104","article-title":"Effect of alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis","volume":"132","author":"Dalakas","year":"2009","journal-title":"Brain"},{"issue":"10","key":"10.1016\/j.autrev.2026.104056_bb0315","first-page":"2080","article-title":"Alemtuzumab (Campath-1H) for treatment of refractory polymyositis","volume":"35","author":"Thompson","year":"2008","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104056_bb0320","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1136\/bjo.84.1.107","article-title":"Campath-1H therapy in refractory ocular inflammatory disease","volume":"84","author":"Dick","year":"2000","journal-title":"Br J Ophthalmol"},{"issue":"12","key":"10.1016\/j.autrev.2026.104056_bb0325","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1093\/rheumatology\/keg424","article-title":"Remission induction in beh\u00e7et\u2019s disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H","volume":"42","author":"Lockwood","year":"2003","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.autrev.2026.104056_bb0330","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/RHU.0b013e318284735c","article-title":"Remission induction in a case of refractory beh\u00e7et disease with alemtuzumab","volume":"19","author":"Perez-Pampin","year":"2013","journal-title":"J Clin Rheumatol"},{"issue":"10","key":"10.1016\/j.autrev.2026.104056_bb0335","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.3899\/jrheum.141344","article-title":"Alemtuzumab as remission induction therapy in beh\u00e7et disease: a 20-year experience","volume":"42","author":"Mohammad","year":"2015","journal-title":"J Rheumatol"},{"issue":"4","key":"10.1016\/j.autrev.2026.104056_bb0340","first-page":"668","article-title":"Progressive multifocal leucoencephalopathy with beh\u00e7et\u2019s disease: an insight into pathophysiology","volume":"56","author":"Agarwal","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.autrev.2026.104056_bb0345","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000194","article-title":"Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months","volume":"3","author":"De Mercanti","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.autrev.2026.104056_bb0350","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00296-019-04467-6","article-title":"Biologic therapy in the idiopathic inflammatory myopathies","volume":"40","author":"Khoo","year":"2020","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2026.104056_bb0355","first-page":"588","article-title":"Blood gamma delta+ t cells and natural killer cells in beh\u00e7ets disease","volume":"19","year":"1992","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2026.104056_bb0360","doi-asserted-by":"crossref","unstructured":"Kural-Seyahi E, Fresko I, Seyahi N, et al. The long-term mortality and morbidity of behcet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore). 2003;82:60\u201376.","DOI":"10.1097\/00005792-200301000-00006"},{"key":"10.1016\/j.autrev.2026.104056_bb0365","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1111\/j.1365-2133.1995.tb16946.x","article-title":"Immunohistology of skin pathergy reaction in beh\u00e7ets disease","volume":"132","author":"G\u00fcl","year":"1995","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2026.104056_bb0370","first-page":"189","article-title":"Immunohistology of oral lesions from patients with recurrent oral ulcers and beh\u00e7ets syndrome","volume":"78","author":"Poulter","year":"1989","journal-title":"Clin Exp Immunol"},{"issue":"6","key":"10.1016\/j.autrev.2026.104056_bb0375","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/s41409-018-0173-x","article-title":"Five year follow-up after autologous peripheral blood hematopoietic stem cell transplantation for refractory, chronic, corticosteroid-dependent systemic lupus erythematosus: effect of conditioning regimen on outcome","volume":"53","author":"Burt","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.autrev.2026.104056_bb0380","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1182\/blood-2008-07-168286","article-title":"Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system","volume":"113","author":"Alexander","year":"2009","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.autrev.2026.104056_bb0385","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1177\/1352458518771276","article-title":"Acute sarcoidosis in a multiple sclerosis patient after alemtuzumab treatment","volume":"24","author":"Graf","year":"2018","journal-title":"Mult Scler"},{"issue":"12","key":"10.1016\/j.autrev.2026.104056_bb0390","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1177\/1352458519898113","article-title":"Alemtuzumab-related eosinophilic central nervous system vasculitis","volume":"26","author":"Leach","year":"2020","journal-title":"Mult Scler"},{"key":"10.1016\/j.autrev.2026.104056_bb0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.clineuro.2023.107675","article-title":"An unforeseen reality: hemophagocytic lymphohistiocytosis following alemtuzumab treatment for a multiple sclerosis","volume":"228","author":"O\u0161ep","year":"2023","journal-title":"Clin Neurol Neurosurg"},{"issue":"7","key":"10.1016\/j.autrev.2026.104056_bb0400","first-page":"2052","article-title":"IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H)","volume":"119","author":"Jones","year":"2009","journal-title":"J Clin Invest"},{"issue":"7","key":"10.1016\/j.autrev.2026.104056_bb0405","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1136\/jnnp-2013-307042","article-title":"Predicting autoimmunity after alemtuzumab treatment of multiple sclerosis","volume":"85","author":"Azzopardi","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"50","key":"10.1016\/j.autrev.2026.104056_bb0410","doi-asserted-by":"crossref","first-page":"20200","DOI":"10.1073\/pnas.1313654110","article-title":"Human autoimmunity after lymphocyte depletion is caused by homeostatic t-cell proliferation","volume":"110","author":"Jones","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11","key":"10.1016\/j.autrev.2026.104056_bb0415","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.1002\/eji.200535075","article-title":"Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis","volume":"35","author":"Cox","year":"2005","journal-title":"Eur J Immunol"},{"issue":"12","key":"10.1016\/j.autrev.2026.104056_bb0420","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.125377","article-title":"Keratinocyte growth factor impairs human thymic recovery from lymphopenia","volume":"5","author":"Coles","year":"2019","journal-title":"JCI Insight"},{"issue":"6","key":"10.1016\/j.autrev.2026.104056_bb0425","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1182\/blood-2006-07-035766","article-title":"Development of a secondary autoimmune disorder after hematopoietic stem cell transplantation for autoimmune diseases: role of conditioning regimen used","volume":"109","author":"Loh","year":"2007","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.autrev.2026.104056_bb0430","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000868","article-title":"Mitigating alemtuzumab-associated autoimmunity in MS: a \u201cwhack-a-mole\u201d b-cell depletion strategy","volume":"7","author":"Meltzer","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"4","key":"10.1016\/j.autrev.2026.104056_bb0435","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41584-026-01357-7","article-title":"Immune reset and immune retune: Approaching cure?","volume":"22","author":"Isaacs","year":"2026","journal-title":"Nat Rev Rheumatol"},{"issue":"9","key":"10.1016\/j.autrev.2026.104056_bb0440","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41584-024-01139-z","article-title":"Advancements and challenges in CAR t cell therapy in autoimmune diseases","volume":"20","author":"Schett","year":"2024","journal-title":"Nat Rev Rheumatol"},{"issue":"16","key":"10.1016\/j.autrev.2026.104056_bb0445","doi-asserted-by":"crossref","first-page":"1630569","DOI":"10.3389\/fimmu.2025.1630569","article-title":"CAR-T cell therapies in autoimmune rheumatic diseases: a brief report on the clinical trial landscape, current status, and future perspectives","volume":"22","author":"Xu","year":"2025","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.autrev.2026.104056_bb0450","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1007\/s00210-025-04425-z","article-title":"CAR t cell therapy efficacy and safety in SLE: a systematic review and pooled analysis of 47 patients across 10 studies","volume":"399","author":"Sayed","year":"2026","journal-title":"Naunyn Schmiedeberg\u2019s Arch Pharmacol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104056_bb0455","doi-asserted-by":"crossref","first-page":"2627057","DOI":"10.1080\/07853890.2026.2627057","article-title":"From technological iteration to clinical breakthrough: advances of CAR-T cell therapy in autoimmune diseases","volume":"58","author":"Yu","year":"2026","journal-title":"Ann Med"},{"issue":"6","key":"10.1016\/j.autrev.2026.104056_bb0460","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1182\/blood.V73.6.1431.1431","article-title":"Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype","volume":"73","author":"Dyer","year":"1989","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.autrev.2026.104056_bb0465","doi-asserted-by":"crossref","first-page":"4581","DOI":"10.1182\/blood.V92.12.4581","article-title":"Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection","volume":"92","author":"Hale","year":"1998","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.autrev.2026.104056_bb0470","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1089\/scd.1.1994.3.15","article-title":"CAMPATH-1 monoclonal antibodies in bone marrow transplantation","volume":"3","author":"Hale","year":"1994","journal-title":"J Hematother"},{"key":"10.1016\/j.autrev.2026.104056_bb0475","doi-asserted-by":"crossref","first-page":"1519671","DOI":"10.3389\/fimmu.2024.1519671","article-title":"CAR-T cell therapy: developments, challenges and expanded applications from cancer to autoimmunity","volume":"15","author":"Kong","year":"2025","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2026.104056_bb0480","doi-asserted-by":"crossref","first-page":"e212","DOI":"10.1016\/S2665-9913(24)00240-6","article-title":"Barriers to CAR t-cell therapy in rheumatology","volume":"7","author":"Lungova","year":"2025","journal-title":"Lancet Rheumatol"},{"issue":"6","key":"10.1016\/j.autrev.2026.104056_bb0485","doi-asserted-by":"crossref","first-page":"e424","DOI":"10.1016\/S2665-9913(25)00091-8","article-title":"Local immune effector cell-associated toxicity syndrome in CAR t-cell treated patients with autoimmune disease: an observational study","volume":"7","author":"Hagen","year":"2025","journal-title":"Lancet Rheumatol"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997226000704?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997226000704?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T15:20:31Z","timestamp":1777130431000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997226000704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":97,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1568997226000704"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104056","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-CD52 therapy of rheumatic diseases: Revisited in the era of immune reset","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104056","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104056"}}